SEC Company Response from Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802) (KPTI) — Apr 22, 2019
Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802)
Date: April 22, 2019 · CIK: 0001503802 · Accession: 0001193125-19-113260
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226038
Letter
KARYOPHARM THERAPEUTICS INC.
85 WELLS AVENUE, SECOND FLOOR
NEWTON, MA 02459
April 22,
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Karyopharm Therapeutics Inc.
Post-Effective Amendment No. 2 to Form S-3 Registration Statement
File No. 333-226038
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Karyopharm Therapeutics Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Post-Effective Amendment No. 2 to Form S-3 Registration Statement (File No. 333-226038), so that it may become effective at 4:00 p.m. Eastern time on April 24, 2019, or as soon thereafter as practicable.
Very truly yours,
Karyopharm Therapeutics Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP KARYOPHARM THERAPEUTICS INC. 85 WELLS AVENUE, SECOND FLOOR NEWTON, MA 02459 April 22, 2019 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Karyopharm Therapeutics Inc. Post-Effective Amendment No. 2 to Form S-3 Registration Statement File No. 333-226038 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Karyopharm Therapeutics Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Post-Effective Amendment No. 2 to Form S-3 Registration Statement (File No. 333-226038), so that it may become effective at 4:00 p.m. Eastern time on April 24, 2019, or as soon thereafter as practicable. Very truly yours, Karyopharm Therapeutics Inc. By: /s/ Christopher B. Primiano Name: Title: Christopher B. Primiano Executive Vice President, Chief Business Officer, General Counsel and Secretary